Bytzer Peter, Langkilde Lars K, Christensen Erik, Meineche-Schmidt Villy
Medicinsk Afdeling, Køge Sygehus, Lykkebækvej 1, Køge, Denmark.
Dan Med J. 2012 Jul;59(7):A4461.
Lost productivity accounts for a significant part of the costs caused by gastrointestinal symptoms. We aimed to describe selfreported productivity in patients presenting with dyspepsia.
Data were sourced from a randomized, double-blinded study of two weeks of esomeprazole 40 mg or placebo in 805 primary-care patients with uninvestigated dyspepsia. Work productivity was tested using the Work Productivity and Activity Impairment questionnaire. Treatment effect on work productivity loss was tested according to the likelihood of treatment response.
A total of 401/805 employed patients were included in the analysis. The average work productivity loss in the past seven days was 10.5 working hours/week. The productivity loss grew with increasing severity of symptoms at baseline. Following two weeks of treatment, the mean improvement in work productivity was significantly higher for both absenteeism (1 hour versus 0.1 hour, p < 0.05) and presenteeism (5.3 hours versus 4.3 hours, p < 0.05) in patients treated with esomeprazole versus placebo. The most substantial improvement was seen in patients who, based on baseline symptoms, were assessed to be likely treatment responders.
Dyspepsia symptoms represent a significant economic burden in terms of lost productivity. The RESPONSE algorithm is successful in determining which patients will benefit from acid suppression in terms of enhanced productivity.
生产力损失在胃肠道症状所致成本中占很大一部分。我们旨在描述消化不良患者自我报告的生产力情况。
数据来源于一项针对805例未经调查的消化不良初级保健患者进行的为期两周的埃索美拉唑40毫克或安慰剂的随机双盲研究。使用工作生产力和活动受损问卷对工作生产力进行测试。根据治疗反应的可能性测试治疗对工作生产力损失的影响。
共有401/805名受雇患者纳入分析。过去七天的平均工作生产力损失为每周10.5个工作小时。生产力损失随基线症状严重程度的增加而增加。治疗两周后，与安慰剂相比，接受埃索美拉唑治疗的患者在旷工（1小时对0.1小时，p<0.05）和出勤但生产力下降（5.3小时对4.3小时，p<0.05）方面的工作生产力平均改善显著更高。在根据基线症状评估为可能对治疗有反应的患者中观察到最大程度的改善。
消化不良症状在生产力损失方面构成重大经济负担。RESPONSE算法在确定哪些患者将从抑酸治疗中提高生产力方面是成功的。
